Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-Blind, Placebo Controlled Trial
Information source: University of Texas Southwestern Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Vasomotor Rhinitis
Intervention: esomeprazole (Drug); placebo (Drug)
Phase: N/A
Status: Completed
Sponsored by: University of Texas Southwestern Medical Center Official(s) and/or principal investigator(s): David A Khan, MD, Principal Investigator, Affiliation: Department of Allergy and Immunology, UT Southwestern
Summary
The purpose of this study was to see if high dose esomeprazole (40mg bid) was effective in
treating non-allergic rhinitis
Clinical Details
Official title: Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-Blind, Placebo Controlled Trial
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Nasal Symptom scores
Secondary outcome: non-nasal symptom scoresreflux scores quality of life scores
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- age between 18-80, symptoms of perennial rhinitis, negative epicutaneous skin testing
to a panel of common aeroallergens, and ability to speak English
Exclusion Criteria:
- pregnancy or breast-feeding, evidence of positive skin tests to a common
aeroallergen, treatment with a proton pump inhibitor within the month prior to
enrollment, treatment with any other anti-reflux therapy within the last month on a
daily basis or within the last two weeks on an as needed basis, and other
gastrointestinal disorders leading to reflux symptoms
Locations and Contacts
Clinical Trials Office, Aston Building, UT Southwestern, Dallas, Texas 75390-9016, United States
Additional Information
Starting date: June 2005
Last updated: August 29, 2008
|